Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL2295019 | 1.00 | ROCK2 (0.30) | ROCK2 | |
| SCHEMBL789393 | 0.96 | — | — | |
| SCHEMBL9517341 | 0.93 | PIK3CD (0.31) | ROCK2 | |
| Ammonia Solution, Strong SCHEMBL25436300 | 0.93 | ROCK2 (0.30) | ROCK2 | |
| SCHEMBL8991362 | 0.93 | ROCK2 (0.30) | ROCK2 | |
| SCHEMBL11238183 | 0.84 | — | — | |
| SCHEMBL5892235 | 0.82 | — | — | |
| SCHEMBL3366507 | 0.82 | — | — | |
| SCHEMBL3366504 | 0.82 | — | — | |
| SCHEMBL247006 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847196-B1 | NEW 2,3-DIHYDRO-FURO[2,3-C]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BOEHRINGER INGELHEIM INT (DE) | 2017-10-25 | — | — | EP | disclosed |
| EP-2847196-A1 | NEW 2,3-DIHYDRO-FURO[2,3-C]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Boehringer Ingelheim International GmbH (DE) | 2015-03-18 | — | — | EP | disclosed |
| US-8809361-B2 | 2,3-dihydrofuro[2,3-c]pyridines, their use as modulators of the G-protein-coupled receptor GPR119 and pharmaceutical compositions thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| WO-2013167514-A1 | NEW 2,3-DIHYDRO-FURO[2,3-C]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-14 | — | — | WO | disclosed |
| US-20130296354-A1 | 2,3-DIHYDROFURO[2,3-c]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8022239-B2 | Mechanism-based inactivators of autotaxin | THE UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-7999136-B2 | Amide compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100136650-A1 | MECHANISM-BASED INACTIVATORS OF AUTOTAXIN | THE UNIVERSITY OF MEMPHIS | 2010-06-03 | — | — | US | disclosed |
| WO-2010040080-A1 | MECHANISM-BASED INACTIVATORS OF AUTOTAXIN | PARRILL-BAKER ABBY LOUISE (US) | 2010-04-08 | — | — | WO | disclosed |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2151431-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-02-10 | — | — | EP | disclosed |
| EP-2143709-A1 | AMIDE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056640-A1 | AMIDE COMPOUND AND USE THEREOF | NAT1, AGXT, HAX1 | ROCK2 3680/4885 |
| US-20100136650-A1 | MECHANISM-BASED INACTIVATORS OF AUTOTAXIN | ENPP2, PLA2G12A, PLA2G10 | ROCK2 2992/4885 |
| US-20100069499-A1 | AMIDE COMPOUND AND USE THEREOF | CBR1, CBR3, GBA1 | ROCK2 3110/4885 |
| US-20130296354-A1 | 2,3-DIHYDROFURO[2,3-c]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS THEREOF | GPR119, GPR3, GPR4 | ROCK2 1760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.